References
- Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607.
- Pouliot MC, Despres JP, Nadeau A. Visceral obesity in men: associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes. 1992;41:826–834.
- Abate N, Garg A, Peshock RM, et al. Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes. 1996;45:1684–1693.
- Isomaa B, Almgren P, Tuomi T. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689.
- Grundy SM, Cleeman JI, Daniels SR. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev. 2005;13:322–327.
- Jiang S, Han J, Li T. Curcumin as a potential protective compound against cardiac diseases. Pharmacol Res. 2017;119:373–383.
- Shin SJ, Lim JH, Chung S, et al. Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet induced renal lipotoxicity in spontaneously hypertensive rats. Hypertens Res. 2009;32:835–845.
- Chopra K, Tiwari V, Arora V, et al. Sesamol suppresses neuro-inflammatory cascade in experimental model of diabetic neuropathy. J Pain. 2010;11:950–957.
- Nepal S, Malik S, Sharma AK, et al. Abresham ameliorates dyslipidemia, hepatic steatosis and hypertension in high-fat diet fed rats by repressing oxidative stress, TNF-α and normalizing NO production. Exp Toxicol Pathol. 2012;64:705–712.
- Joe B, Vijaykumar M, Lokesh BR. Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr. 2004;44:97–111.
- Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol. 2007;595:105–125.
- Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as “Curecumin from kitchen to clinic”. Biochem Pharmacol. 2008;75:787–809.
- Reuter S, Gupta SC, Park B, et al. Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr. 2011;6:93–108.
- Momtazi AA, Banach M, pirro M, et al. Regulation of PCSK9 by nutraceuticals. Pharmacol Res. 2017;120:157–169.
- Monsalve FA, Pyarasani RD, Delgado-Lopez F, et al. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm. 2013;2013:549627.
- Kang ES, Kim GH, Kim HJ, et al. Nrf2 regulates curcumin-induced aldose reductase expression indirectly via nuclear factor-κB. Pharmacol Res. 2008;58:15–21.
- Nelson KM, Dahlin JL, Bisson J, et al. The essential medicinal chemistry of curcumin. J Med Chem. 2017;60:1620–1637.
- Ganjali S, Blesso CN, Banach M, et al. Effects of curcumin on HDL functionality. Pharmacol Res. 2017;119:208–218.
- Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645–650.
- Laudet V, Hanni C, Coll J, et al. Evolution of the nuclear receptor gene superfamily. EMBO J. 1992;11:1003–1013.
- Morbidelli L. Polyphenol-based nutraceuticals for the control of angiogenesis: analysis of the critical issues for human use. Pharmacol Res. 2016;111:384–393.
- Jacob A, Wu R, Zhou M, et al. Mechanism of the anti-inflammatory effect of curcumin: PPAR-gamma activation. PPAR Res. 2007;2007:89369.
- Li H, Yang M, Li Z, et al. Curcumin inhibits angiotensin II-induced inflammation and proliferation of rat vascular smooth muscle cells by elevating PPAR-γ activity and reducing oxidative stress. Int J Mol Med. 2017;39:1307–1316.
- Mazdi M, karimi E, Meydani M. Potential effects of curcumin on peroxisome proliferator-activated receptor-γ in vitro and in vivo. World J Methodol. 2016;6:112–117.
- Huang TH, Kota BP, Razmovski V, et al. Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome. Basic Clin Pharmacol Toxicol. 2005;96:3–14.
- Cronet P, Petersen JFW, Folmer R, et al. Structure of the PPAR[alpha] and -[gamma] ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure. 2001;9:699–706.
- Primev, Schrödinger, LLC, New York, NY, 2015.
- Yamashita F, Hashida M. In silico approaches for predicting ADME properties of drugs. Drug Metab Pharmacokinet. 2004;19:327–338.
- Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3–26.
- Jorgensen WL. Efficient drug lead discovery and optimization. Acc Chem Res. 2009;42:724–733.
- Hess B, Kutzner C, van der Spoel D, et al. GRGMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput. 2008;4:435–447.
- Revathy S, Elumalai S, Benny M, et al. Isolation, purification and identification of curcuminoids from turmeric (Curcuma longa L.) by column chromatography. J Exp Sci. 2011;2:21–25.
- Saladini M, Lazzari S, Pignedoli F, et al. New synthetic glucosyl-curcuminoids and their 1H and 13C NMR characterization from Curcuma longa. Plant Foods Hum Nutr. 2009;64:224–229.
- Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
- Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351–358.
- Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med. 1963;61:882–888.
- Hong D, Zeng X, Xu W. Altered profiles of gene expression in curcumin-treated rats with experimentally induced myocardial infarction. Pharmacol Res. 2010;61:142–148.
- Dolber PC, Spach MS. Picrosirius red staining of cardiac muscle following phosphomolybdic acid treatment. Stain Technol. 1987;62:23–26.